Background: The A risk allele of rs9939609 of the fat mass-and obesity-associated gene (FTO) increases body fat mass. Objective: To examine whether FTO rs9939609 affects obese individuals' response to a high-fat, low-carbohydrate (CHO) (HF) or low-fat, high-CHO (LF), hypo-energetic diet and whether the effect of the FTO variant depends on dietary fat and CHO content. Design: In a 10-week, European, multi-centre dietary intervention study 771 obese women and men were randomized to either LF (20-25% of energy (%E) from fat, 60-65%E from CHO) or HF (40-45%E from fat, 40-45%E from CHO), hypo-energetic diet (measured resting metabolic rate multiplied by 1.3-600 kcal day À1 ). Body weight, fat mass (FM), fat-free mass (FFM), waist circumference (WC), resting energy expenditure (REE), fasting fat oxidation as % of REE (FatOx), insulin release (HOMA-b) and a surrogate measure of insulin resistance (HOMA-IR) were measured at baseline and after the intervention. In all, 764 individuals were genotyped for FTO rs9939609. Results: For A-allele carriers the drop-out rate was higher on HF than LF diet (in AT, P ¼ 0.002; in AT/AA combined, P ¼ 0.003). Among those individuals completing the intervention, we found no effect of FTO rs9939609 genotype on Dweight, DFM, DFFM, DWC or DFatOx. However, participants with TT had a smaller reduction in REE on LF than on HF diet (75 kcal/24 h; interaction: P ¼ 0.0055). These individuals also showed the greatest reduction in HOMA-b and HOMA-IR (interaction: P ¼ 0.0083 and P ¼ 0.047).
Introduction
Genome-wide association studies discovered an obesity locus in a highly conserved region of strong linkage disequilibrium in the fat mass and obesity-associated gene (FTO).
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The role of FTO variants as predisposing to obesity in Caucasian populations is now established more firmly. [5] [6] [7] [8] The association to general fatness irrespective of its distribution is confirmed throughout the range of fatness 9 and the association between FTO variants and obesity is also seen in Japanese people. 10 In search for the mechanism by which allelic variation in FTO affect adiposity, both central 11 and peripheral 12, 13 mechanisms have been examined. Several studies indicate that FTO variants are associated with appetite 14 and energy intake, 15, 16 whereas energy expenditure is unaffected. [15] [16] [17] Although it is possible that the observed associations between FTO single nucleotide polymorphisms (SNP)s and obesity are caused by KIAA1005 located 200 bp upstream of the 5 0 end of FTO, 1 it is a natural assumption that effects of SNPs in FTO on obesity are mediated through the effects of FTO itself. Studies in rodents provide evidence supporting a central role for Fto in the regulation of energy balance. [18] [19] [20] These studies suggest that FtoFlike the majority of genetic defects associated with obesityFhas its principal impact on the function of the hypothalamus, although the results are inconsistent. In a 48-h deprivation model performed in mice Fto mRNA levels in arcuate nucleusFwhich is of critical importance for the control of energy balanceFwere reduced by B60% in fasted compared with freely feeding mice. A similar effect of starvation on hypothalamic Fto expression was seen in another mouse study, 20 whereas the opposite effect was found in rats. 18 It is of potential importance to identify individuals with a genetic pattern that influences the response to weight reduction therapy, but it is still unclear if variants in FTO affect weight loss in obese individuals. Two studies are published with findings of no association between FTO variants (rs8050136 and rs9939609, respectively) and weight loss. 21, 22 Further, it is unknown whether factors, such as macronutrient composition, affect the association between variants in FTO and weight loss. Previously 42 SNPs in 26 candidate genes for obesity (not including FTO) were examined in relation to weight loss in the NUGENOB study (Nutrient-gene interaction in human obesity: implication for dietary guidelines), in which average weight loss was 6.8 kg after 10 weeks. 23 The results suggested that the 42
SNPs under study did not have any major impact on weight reduction during short-term either high-fat (HF) or low-fat (LF) hypo-energetic diet in obese individuals. In this context we decided to investigate the effect of FTO rs9939609 on diet-induced weight loss and associated phenotypes including possible interactions with macronutrient content of the weight loss diet in the NUGENOB-cohort.
Methods
The NUGENOB study was a randomized, parallel, two-arm, open label, 10-week dietary intervention (trial registration: ISRCTN25867281) of two hypo-energetic diets with either low (LF) or high fat content (HF). NUGENOB was a multi-centre study including eight clinical centres in seven European countries (Sweden, Denmark, UK, The Netherlands, Czech Republic, France (two clinical centres), and Spain) and has been described in detail elsewhere (www.nugenob.org). 23, 24 Participants were recruited from May 2001 until September 2002 through the media, from waiting lists or ongoing population studies and by self-referral or referral from a general practitioner or other clinical units and local obesity organizations. Inclusion criteria were: body mass index (BMI; kg m À2 ) X30, and age 20-50 years. Exclusion criteria were: weight change 43 kg within 3 months before the start of the study; hypertension, diabetes or hyperlipidemia treated by drugs; untreated thyroid disease; surgically or drug-treated obesity; pregnancy; participation in other trials and alcohol or drug abuse.
The target macronutrient composition of the two diets was: LF diet: 20-25% of total energy from fat, 15% from protein and 60-65% from carbohydrate; HF diet: 40-45% of total energy from fat, 15% from protein and 40-45% from carbohydrate. Both diets were designed to provide 600 kcal day À1 (2510 kJ day
À1
) less than the individually estimated daily energy requirement based on measured initial resting metabolic rate multiplied by 1.3. Participants were given oral and written instructions relating to these targets based on either a template (see details at www.nugenob.org) or exchange system. 25 Instructions were also given to minimize differences between the two diets in other components such as sources and type of fat, amount and type of fibre, type of carbohydrate, fruit and vegetables and meal frequency and participants were requested to abstain from alcohol consumption. Dietary instructions were reinforced weekly. Seven hundred and seventy-one obese white Europeans (579 women) were included and randomized to one of the two intervention diets by stratified block randomization. The randomization list was computer generated at the coordinating centre and the block size was unknown to the clinical centres. Informed written consent was obtained before study participation and the study was approved by the Ethical Committee at each participating centres.
Phenotypes
Before randomization to the weight loss intervention and after completion of the intervention, participants underwent a clinical investigation protocol starting at 0800 h after a 12 h overnight fast. The first clinical investigation was preceded by a 3-day dietary run in the period during which participants had to keep to their habitual diet, avoid excessive physical activity and alcohol consumption. The second clinical investigation was conducted in the tenth week after start of the dietary weight loss intervention programme.
Anthropometrics and body composition were assessed after the participants voided the bladder. Body weight was At the second clinical investigation day indirect calorimetry measurements on some of or all participants completing the intervention were carried out in six of eight centres (Sweden, UK, Czech Republic, France (both centres) and Spain). After participants rested supine for 15 min, venous blood samples were drawn to determine fasting plasma glucose and fasting plasma insulin. Plasma glucose concentrations (ABX diagnostics, Montpellier, France) were measured on a COBAS MIRA automated spectro-photometric analyzer (Roche diagnostica, Basel, Switzerland). Plasma insulin concentrations were measured with a double antibody radio-immunoassay (Insulin RIA 100, Kabi-Pharmacia, Uppsala, Sweden). Homeostasis model assessment (HOMA) 28 was used to estimate insulin release (HOMA-b) and a surrogate measure of whole-body insulin resistance (HOMA-IR).
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Genotyping Samples of buffy coat were sent on dry ice to the Steno Diabetes Center in Copenhagen, where DNA was extracted. Extracted DNA samples were diluted in Tris/EDTA buffer to a stock DNA solution of 100 ng ml À1 and a working DNA solution of 10 ng ml
À1
. Stock solutions were stored at À80 1C, working solutions were stored at 4 1C. DNA samples were stored and handled in locations free of contaminating polymerase chain reaction products.
High-throughput genotyping of the FTO rs9939609 SNP was performed using Taqman allelic discrimination (KBioScience, Herts, UK). DNA samples were available for 764 individuals. There was a 96.9% genotyping success rate (n ¼ 734) and the genotyping error rate was 0.27%.
Statistical modelling
Examination of Hardy-Weinberg equilibrium was carried out while taking into account centre differences by summing up Pearson's w 2 statistics for each centre and comparing with a w 2 distribution with 8 degrees of freedom.
First, general genetic models with no assumption of a specific effect of the risk allele (A) in individuals heterozygous and homozygous for the A allele compared with non-carriers (null hypothesis) were analysed. The results from these analyses were then used to decide whether to proceed with analyzing models assuming a particular effect of the risk allele (A) compared with the major allele T: dominant effect (TT ¼ 0, AT and AA ¼ 1), co-dominant effect (assessed as an additive effect:
. Regression models examining interaction between genotype and diet were made and if no interaction was found models examining the main effects of rs9939609 were made.
Change (D) in body weight in kg, DFM (kg), DFFM (kg), DWC (cm), DHOMA-b, DHOMA-IR, DREE (kcal/24 h) and DFatOx (%) were calculated by subtracting measurement recorded immediately before randomization from the measurement recorded at the completion of the intervention. The effects (with 95% confidence intervals (95% CIs)) of rs9939609 genotype (TT, AT or AA) combined with the assigned hypo-energetic diet (HF or LF) on Dweight, DFM, DFFM, DWC, DHOMA-b, DHOMA-IR, DREE and DFatOx were estimated by separate linear regression models for each outcome variable. Drop out was similarly analysed by logistic regression models and additionally by time-to-event analysis. In models for changes in phenotypes we controlled for respective baseline values (linear; separate effect of weight, WC, FM and FFM for men and women; FM, HOMA-b, and HOMA-IR were log transformed), age (linear in models of DFFM, DHOMA-b, DHOMA-IR, DREE and DFatOx; linear and squared in models of Dweight, DFM and DWC), sex and centre (Gaussian random effect). Models for DREE were additionally adjusted for baseline FFM and DFFM. Odds ratios (OR) and hazard ratios (HR) of drop out according to genotype and randomized diet combined was analysed adjusting for baseline BMI (linear), age (linear), sex and centre.
Assessment of main effects was conducted by including the genotypes as covariates and as a separate covariate the diet group to which the participants had been randomized. Gene-diet interaction analyses were carried out by estimating the genotype-specific difference in mean Dweight, DFM, DFFM, DWC, DHOMA-b, DHOMA-IR, DREE and DFatOx, respectivelyFadjusted as described aboveFbetween LF and the HF. This allowed a comparison of the differences in mean Dweight, DFM, DFFM, DWC, DHOMA-b, DHOMA-IR, DREE and DFatOx, respectively for AT and/or AA with TT or TT and AT depending on an assumed genetic model.
The statistical software STATA version 9.0 (Stata, College Station, TX, USA), was used for all statistical analyses.
Results
FTO rs9939609 was genotyped successfully in 734 of the 771 obese individuals randomized to one of the two diets. The rs9939609 allele frequencies were in Hardy-Weinberg equilibrium (P ¼ 0.97).
In randomizing participants to the two hypo-energetic diets FTO rs9939609 genotype was not distributed evenly FTO rs9939609 and randomized hypo-energetic diet K Grau et al (P ¼ 0.027) between HF and LF diet. Individuals with TT genotype were more likely to have been randomized to HF (55.2%) than LF diet (44.8%), heterozygous individuals (AT) were distributed evenly between the two diets and individuals homozygous for the risk allele (AA) were more likely to have been randomized to LF (59.2%) than to HF diet (40.8%).
In total 115 of the successfully genotyped individuals failed to complete the 10-week weight loss intervention. Table 1 presents drop out according to genotype and diet. In TT drop-out percentage was higher for those randomized to LF (21.4%) than for those randomized to HF diet (14.6%). For carriers of the variant A allele drop out percentage was higher on HF (AT: 17.8%; AA: 28.3%) than LF diet (AT: 6.7%; AA: 16.9%). Adjusting for baseline BMI, age, sex and centre, we found a significant interaction between FTO rs9939609 genotype and hypo-energetic diet (P for interaction ¼ 0.020) on odds for drop out (Figure 1 ) and in a dominant model odds for drop out was higher on the HF diet than on the LF diet (P ¼ 0.0030) for A allele carriers. When analysing without assuming a genetic model the difference was significant for the AT genotype (P ¼ 0.0022), but not for the AA genotype alone (P ¼ 0.26). Time-to-event analyses of drop out gave similar results (not shown, can be obtained from the corresponding author on request).
Mean values for anthropometrics and metabolic variables at baseline and mean change during intervention are presented in Table 2 according to genotype and diet. Among individuals who completed the intervention and for whom FTO rs9939609 was genotyped we found no effect of FTO rs9939609 genotype on Dweight, DFM, DFFM, DWC or DFatOx (Table 2) . Mean Dweight among successfully genotyped participants completing the intervention was À6.80 kg consisting of À5.35 kg DFM and À1.47 kg DFFM. WC decreased on average by 6.33 cm, whereas FatOx increased by a 2.5 percentage points from 46.6 to 49.1% of REE.
We found significant interactions between genotype (AT and AA vs TT) and diet in relation to DREE (P ¼ 0.0055; n ¼ 387). The combined effects of genotype and diet on DREE are presented in Figure 2a . Mean DREE was À114 kcal/24 h. For individuals with TT genotype decrease in REE was 75 kcal/24 h smaller (P ¼ 0.006) for individuals randomized to the LF than HF diet. The decrease in REE was 74 kcal/24 h smaller (P ¼ 0.003) for TT genotype on LF than AT/AA on LF. For AT/AA genotype there was no significant difference in DREE between LF and HF diet (P ¼ 0.33).
We also found interaction between genotype (AT and AA vs TT) and diet for DHOMA-b (P ¼ 0. 
Discussion
In this weight loss intervention study drop out was statistically related to FTO rs9939609 genotype and macronutrient content of the hypo-energetic diet (HF vs LF). Among A allele carriers the risk of drop out was higher when randomized to HF diet than when randomized to LF diet. For individuals completing the intervention we found no effects of FTO rs9939609 genotype on Dweight, DFM, DFFM, DWC FTO rs9939609 and randomized hypo-energetic diet K Grau et al Statistical analyses were carried out for the variables relevant to the objective of the study. P-values from linear regressions adjusting for baseline weight (linear; separate effect for men and women), fat-free mass (FFM) (linear; separate effect for men and women), fat mass (FM) (log-transformed; linear; separate effect for men and women), waist circumference (WC) (linear; separate effect for men and women), and fat oxidation (FatOx) (linear) respectively along with age (linear in models of DFFM, and DFatOx; linear and squared in models of Dweight, DFM and DWC), sex and centre (Gaussian random effect). No assumption of genetic model. FTO rs9939609 and randomized hypo-energetic diet K Grau et al or DFatOx, but we found statistically significant interactions between FTO rs9939609 genotype and fat and carbohydrate (CHO) content of the hypo-energetic diet in relation to a change in three (DREE, DHOMA-b and DHOMA-IR) of eight investigated obesity-related phenotypes.
In the original analyses of the NUGENOB weight loss intervention not including genotypes a greater drop out was seen among participants randomized to HF than LF diet. 24 Although there was only a significant difference in the risk of drop out between diets for AT genotype (greater on HF than LF) there was also a trend towards a greater drop out on HF diet than LF diet for AA genotype. It would seem more plausible to see an effect in all carriers of the A allele rather than just in heterozygous individuals, but clearly more AA individuals would need to be studied to confirm this. The reason for differences in drop out rates according to the genotype is unclear, but could potentially be explained by preferences for dietary fat vs CHO or metabolic effects. A study by Cecil et al. 15 found the FTO rs9939609 A-allele associated with increased energy intake in children. Intake of all macronutrients tended to be greater in A-allele carriers but especially so for fat intake. In addition, the few studies that examined the relationship between appetite 14 and dietary intakes 16, 31 with FTO, were performed in children or adolescents. In this context, an understanding of the interactions between macronutrient intake or dietary components and the genotype is important to provide a basis for determining the role of dietary intake and habits in the prevalence and pathogenesis of important conditions such as type 2 diabetes and obesity. 32 Two previous studies have examined FTO variants in relation to weight loss interventions. 21, 22 Unfortunately, drop out from the interventions was not analysed in either of these reports. Our finding of no main effects of FTO rs9939609 on change in anthropometrics and metabolic estimates during intervention is in agreement with the two studies. 21, 22 Other studies than the present are suggestive of modifiable effects of FTO variants. 5, 33 Unfortunately, it was not possible to examine the interaction between genotype and fat and CHO content in either of the two previous studies of FTO variants and response to weight loss intervention. In the first study all individuals were allocated to the same lifestyle intervention and in the second study all individuals were given the same dietary recommendations of reduced fat and sugar intake. FTO rs9939609 and randomized hypo-energetic diet K Grau et al
Previous studies suggest that FTO variants associated with obesity are not associated with resting energy expenditure. [15] [16] [17] However, in this study we found an interaction between rs9939609 genotype and the dietary fat and CHO content in DREE. The difference in DREE between LF and HF diet in TT subjects of 75 kcal/24 h may seem small considering baseline values of REE at 1800-1900 kcal/24 h. It is however a difference in DREE of more than 50%. It can be speculated that the greater decrease in REE on a HF than LF diet for TT genotype may expose these individuals to a higher tendency to weight regain, which we unfortunately have no data on. The FTO rs9939609 risk A-allele may be associated with lower whole-body insulin sensitivity. A study in 6000 Danes found that insulin sensitivity was significantly decreased in homozygous carriers and that the impact of the FTO rs9939609 genotype on BMI levels was highly influenced by insulin sensitivity. 5 In the present study we found an interaction between rs9939609 genotype and the dietary fat and CHO content in DHOMA-b and DHOMA-IR. Given the strong association between FTO variants and obesity it may come as a surprise that we did not find an effect of rs9939609 on either Dweight, DWC, DFM or DFFM during a weight loss dieting period. One possible explanation could be that FTO variants primarily influence body fatness early in life and that effect persists into adulthood. The effect of FTO variants on body composition and on the risk of obesity and overweight is observed already in childhood to the same level as seen in adolescence and later in adulthood. 1, 34, 35 Although no association is observed with birth weight or with the ponderal index at birth, 1, 35, 36 already at the age of 2 weeks FTO SNPs are associated with increased weight and ponderal index. 36 Another possible explanation for the lack of association between rs9939609 and Dweight, DWC, DFM and/or DFFM is that weight loss, which mainly is reducing the amount of fat in the adipocytes, from a metabolical and biological point of view, is not the reverse of primary weight gain, which also implies adipogenesis. Analysing the allocated diet (HF or LF) rather than actual diet may have obscured the associations examined in this study. Although average weight loss was as expected indicating that participants on average complied with the 600 kcal day À1 energy deficit the inter-individual variation in weight loss suggests that not all individuals complied fully with the energy restrictionFsome individuals had a higher energy intake and others a lower energy intake than targeted. 24 Similarly, for compliance with fat and CHO content of HF and LF diet; the differences in changes in blood lipids between diets were as expected, but there were considerable inter-individual differences in reported fat and CHO composition within both diets. 23 However, using reported intake has its own problems with potential misreporting and would challenge the advantage of the study's randomized design. As it is seen for FTO rs9939609 genotype in this study randomization is no guarantee for even distribution of potential risk factors between study groups. On the other hand uneven distribution of one risk factor between the two diet groups does not imply that unknown and unmeasured risk factors in general are distributed unevenly. As the multiple statistical testing done in this study is not analogous to repeated testing of the same null hypothesis multiple times and as the choice of analysing FTO is clearly hypothesis-driven the analyses are not adjusted for multiple testing. However, false-positive results cannot be excluded and the results obviously need replication in other studies. Previous analyses comparing the two diets in the NUGENOB study but not including genetic factors led to the conclusion that the LF and HF hypo-energetic diet produced similar mean weight loss and that both diets produced favourable changes in circulating levels of fasting blood lipids, insulin and glucose. 24 Although we found no effect of FTO rs9939609 on weight loss, neither on its own nor in combination with the fat and CHO content of the hypo-energetic diet, the results in the present study suggest that for healthy obese carriers of the FTO rs9939609 risk A-allele the risk of dropping out from the intervention is lower on LF than HF hypo-energetic diet. For non-carriers completing the intervention the decrease in REE was smaller, and the decrease in HOMA-b and HOMA-IR was greater on LF than on a HF diet. LF hypo-energetic diet may thus be preferable to HF hypo-energetic diet for healthy obese wishing to lose weight irrespective of FTO rs9939609 genotype. However, because there have been no previous reports of similar associations these findings need to be replicated in a different population and possible mechanism responsible for these associations should be explored.
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